Posted by Michael Wonder on 03 Oct 2018
Axumin (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS for use in PET imaging of suspected recurrent prostate cancer
2 October 2018 - Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the Transparency Committee of the French Haute Autorité de Santé (HAS) has recommended that Axumin (fluciclovine (18F)) is included on the list of medicines approved in France for hospital use, in line with its European indication.
Axumin is a novel molecular imaging agent approved in the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.
The positive recommendation marks a further milestone in the roll-out of Axumin across Europe, following receipt of Marketing Authorisation from the European Commission on 22 May 2017.
